Pascal Wolter
Overview
Explore the profile of Pascal Wolter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freire M, Martin M, Segers K, Sepulchre E, Leroi N, Coupier J, et al.
J Pers Med
. 2024 Jun;
14(6).
PMID: 38929805
Background/objectives: , , , and are known cancer predisposition genes (CPGs), but tumor risk in patients with simultaneous pathogenic variants (PVs) in CPGs remains largely unknown. In this study, we...
2.
De Paepe K, Van Keerberghen C, Agazzi G, De Keyzer F, Gheysens O, Bechter O, et al.
Radiol Imaging Cancer
. 2021 Apr;
3(2):e200061.
PMID: 33817648
Purpose: To evaluate the prognostic utility of apparent diffusion coefficient (ADC) changes at whole-body diffusion-weighted (WB-DW) MRI after one treatment cycle for aggressive non-Hodgkin lymphoma (NHL) compared with response assessment...
3.
Kim Y, Prince H, Whittaker S, Horwitz S, Duvic M, Bechter O, et al.
Eur J Cancer
. 2021 Apr;
148:411-421.
PMID: 33794441
Introduction: Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin...
4.
Dummer R, Prince H, Whittaker S, Horwitz S, Kim Y, Scarisbrick J, et al.
Eur J Cancer
. 2020 Jun;
133:120-130.
PMID: 32502876
Background: Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 ...
5.
Marasigan V, Guvenc C, Oord J, Stas M, Boecxstaens V, Bechter O, et al.
Acta Derm Venereol
. 2019 Jul;
99(12):1154-1159.
PMID: 31314121
The rising incidence of cutaneous melanoma and its stable high mortality rates despite innovative cancer care, require better prediction of the clinical outcome. In a large cutaneous melanoma population we...
6.
Marasigan V, Guvenc C, van den Oord J, Stas M, Boecxstaens V, Bechter O, et al.
Melanoma Res
. 2019 Jan;
29(6):590-595.
PMID: 30681428
The rising incidence of cutaneous melanoma (CM), an aggressive skin cancer, emphasizes the need for novel biomarkers to guide personalized care and better predict outcome. Genetic factors including germline risk...
7.
Vanmechelen M, Lambrechts D, Van Brussel T, Verbiest A, Couchy G, Schoffski P, et al.
Clin Genitourin Cancer
. 2018 Dec;
17(2):e235-e246.
PMID: 30527746
Background: There are no validated markers that predict response or resistance in patients with metastatic clear-cell renal cell carcinoma (mccRCC) treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors...
8.
Carlino M, Long G, Schadendorf D, Robert C, Ribas A, Richtig E, et al.
Eur J Cancer
. 2018 Aug;
101:236-243.
PMID: 30096704
Background: Predictive biomarkers of patients likely to benefit from anti-programmed death 1 inhibitor therapy have clinical relevance. We examined whether line of therapy or tumour programmed death ligand 1 (PD-L1)...
9.
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al.
Cell
. 2018 Jul;
174(4):843-855.e19.
PMID: 30017245
Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology...
10.
Werbrouck E, Bastin J, Lambrechts D, Verbiest A, Van Brussel T, Lerut E, et al.
Acta Clin Belg
. 2018 May;
74(3):180-188.
PMID: 29792121
Background And Aim: Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) cause significant adverse events including thyroid dysfunction, mainly hypothyroidism, in a considerable proportion of patients. In a series...